34 citations
,
April 2006 in “PubMed” This review discusses current treatments for benign prostatic hyperplasia and reports on the cost-effectiveness of alpha1-selective adrenergic receptor antagonists compared to other pharmacologic and invasive therapies without presenting new clinical results.
6 citations
,
July 2022 in “Journal of health economics and outcomes research” This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls.
2 citations
,
April 2024 in “Cutis” This study reported that despite the limited effectiveness of many current therapies for alopecia areata, patients face substantial financial burdens managing the condition, based on an analysis of ten studies involving approximately 16,000 patients.
March 2026 in “The Journal of Dermatology” This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.
September 2024 in “Journal of the American Academy of Dermatology” Botulinum toxin is not effective or cost-efficient for treating male pattern baldness.